SCHEMBL1622337

SCHEMBL1622337

CC(=O)Nc1nc2ccc(-c3cccc(N)c3)cc2s1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 8/20 0.77
PIK3CA P42336 6/20 0.70
CYP3A4 P08684 3/20 0.69
CLK1 P49759 1/20 0.62
DYRK1A Q13627 6/20 0.60
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
FSCN1 Q16658 1/20 0.59
PDPK1 O15530 1/20 0.59
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
GLA P06280 1/20 0.58
GAA P10253 1/20 0.58
MAPT P10636 1/20 0.58
HPGD P15428 1/20 0.58
NFKB1 P19838 1/20 0.58
HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1653742 0.88 PIK3CG (0.78) PIK3CGPIK3CACYP3A4CLK1DYRK1A
SCHEMBL1651874 0.87 PIK3CG (1.00) PIK3CGPIK3CACYP3A4DYRK1ANPC1
SCHEMBL1651394 0.86 PIK3CG (0.79) PIK3CGPIK3CACYP3A4DYRK1ANPC1
SCHEMBL3716998 0.86 PIK3CG (0.79) PIK3CGPIK3CACYP3A4DYRK1ANPC1
SCHEMBL3870265 0.86 PIK3CG (0.79) PIK3CGPIK3CACYP3A4DYRK1ANPC1
SCHEMBL3711448 0.85 DYRK1A (0.75) PIK3CGPIK3CACYP3A4DYRK1ANPC1
SCHEMBL758050 0.85 CLK1 (0.78) PIK3CGPIK3CACYP3A4CLK1DYRK1A
SCHEMBL798579 0.85 PIK3CG (0.77) PIK3CGPIK3CACYP3A4DYRK1ANPC1
SCHEMBL6068147 0.85 ABL1 (0.79) PIK3CGPIK3CACYP3A4NPC1RAB9A
SCHEMBL20887521 0.84 PIK3CG (0.70) PIK3CGPIK3CACYP3A4DYRK1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183232-B1 PI3 KINASE MODULATORS AND METHODS OF USE AMGEN INC (US) 2013-03-06 EP disclosed
US-7928140-B2 Benzothiazole PI3 kinase modulators for cancer treatment AMGEN INC. (US) 2011-04-19 US disclosed
EP-2183232-A2 PI3 KINASE MODULATORS AND METHODS OF USE Amgen, Inc (US) 2010-05-12 EP disclosed
US-20090054405-A1 PI3 kinase modulators and methods of use AMGEN INC. (US) 2009-02-26 US disclosed
WO-2009017822-A2 PI3 KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054405-A1 PI3 kinase modulators and methods of use PIK3CA, PIK3C2A, PIK3C2B PIK3CG 5/4885PIK3CA 1/4885CYP3A4 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.